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Abstract
Small differences in the chemical structures of ligands can be responsible for agonism, neutral antagonism or inverse
agonism toward a G-protein-coupled receptor (GPCR). Although each ligand may stabilize the receptor conformation in a
different way, little is known about the precise conformational differences. We synthesized the angiotensin II type 1
receptor blocker (ARB) olmesartan, R239470 and R794847, which induced inverse agonism, antagonism and agonism,
respectively, and then investigated the ligand-specific changes in the receptor conformation with respect to stabilization
around transmembrane (TM)3. The results of substituted cysteine accessibility mapping studies support the novel concept
that ligand-induced changes in the conformation of TM3 play a role in stabilizing GPCR. Although the agonist-, neutral
antagonist and inverse agonist-binding sites in the AT1 receptor are similar, each ligand induced specific conformational
changes in TM3. In addition, all of the experimental data were obtained with functional receptors in a native membrane
environment (in situ).
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Introduction
Over the past several decades, an important subject of research
has been how molecules (agonist, neutral antagonist, and inverse
agonist) bind to and change the conformation to activate or
inactivate G-protein coupled receptors (GPCRs) [1,2]. Although
only light-sensitive rhodopsin has been crystallized in different
conformational states [3–5], the crystal structures of the ß-
adrenergic receptors (ARs) ß 1 and ß 2-AR have recently been
obtained for complexes of the receptors bound to inverse agonists
[6,7]. More recently, Rosenbaum et al. [8], Rasmussen et al. [9],
and Warne et al. [10] reported that structural, biophysical and
computational studies could provide insight into the agonist-
induced activation of ß1 and ß2-AR. Based on a comparison of the
agonist-induced crystal structure [8] to that in which ß2-AR is
bound to an inverse agonist [7], it has been shown that the
transition between the R* (active) state and R (inactive) state
involves the repacking of hydrophobic amino acid residues with
slight rotations of transmembrane (TM) 5 and 6. Nonetheless, the
conformation range and dynamics of the effects of ligands on
GPCRs may differ from one receptor to another.
Angiotensin II (Ang II) type 1 (AT1) receptor, which is a
member of the GPCR superfamily, has a widespread tissue
distribution and mediates most known cardiovascular functions
including vasoconstriction, cardiovascular hypertrophy and hy-
perplasia [11]. The AT1 receptor exhibits a low level of
constitutive activity in the absence of any ligand [12]. The data
indicate that a small portion of the receptor is in the active state
(R*). The blockade of constitutive activity may confer resistance to
diverse effects. Inverse agonists inhibit basal constitutive activity,
and we previously reported that the AT1 receptor blocker (ARB)
olmesartan showed inverse agonism toward inositol phosphate (IP)
production [13]. We revealed that cooperative interactions
between the hydroxyl group and Tyr
113 (TM3) and between the
carboxyl group and His
256 (TM6) are crucial for the potent inverse
agonist activity of olmesartan [13]. In addition, the olmesartan-
related compound R239470, which has a non-acidic carbamoyl
group instead of a carboxyl group, acts as a neutral antagonist.
Each inverse agonist, neutral antagonist and agonist may induce a
specific conformational change in TM3 as well as TM6 in the AT1
receptor. However, little is known about this topic, even though it
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receptor interaction.
Small differences in the chemical structures of ligands are
responsible for inducing agonism, neutral antagonism or inverse
agonism in a GPCR [1,14,15]. Although each agonist, neutral
antagonist or inverse agonist may stabilize the receptor confor-
mation in a different way, little is known about the precise
differences in the AT1 receptor. Specifically, little is known about
the structural basis for the functional versatility of the AT1
receptor, which switches from the R state to the R* state under the
influence of ligands. Since the AT1 receptor has not yet been
crystallized, we used an alternate approach in this study.
Structure-based drug-design methods rely on knowledge about
the molecules that bind to the biological target AT1 receptor and
the focus is on ligands, and is usually referred to as receptor-based
drug design [16–18]. In this approach, ligand molecules are built-
up within the constraints of the binding pocket by assembling
small pieces in a stepwise manner. In the present case, since
amino-aromatic bonding between the agonist ‘‘switch’’ Tyr
4 of
Ang II and the agonist switch-binding residue Asn
111 of the AT1
receptor is responsible for initiating receptor activation [19], we
speculated that aromaticity of the ligand as an agonist may be
important for the activation of AT1 receptor. The neutral
antagonist R239470 with an aromatic ring may act as an agonist.
Using the substituted cysteine accessibility mapping (SCAM)
method [20–22], Martin et al. identified the residues within TM3
of the AT1 receptor that contribute to the formation of the binding
site pocket and found that constitutive activation of AT1 receptor
causes slight counterclockwise rotation of TM3 [20]. We
speculated that an inverse agonist, neutral antagonist and agonist
would induce different changes in the conformation of TM3 of
AT1 receptor. To address this question, we systematically mutated
the AT1 receptor and examined whether olmesartan-related
compounds would induce agonism, and subsequently analyzed
the specific action of an inverse agonist, neutral antagonist and
agonist on the receptor conformation with respect to stabilization
around TM3 as assessed by SCAM and molecular modeling of the
AT1 receptor.
Based on the results of these experiments, we developed a new
agonist from the inverse agonist against the AT1 receptor and
demonstrated the ligand-induced specific action on changes in the
conformation of TM3 in the receptor.
Results
Synthesis of Olmesartan-related Compounds
As shown in Fig. 1, we syntesized olmesartan-related com-
pounds (R781253, R781254, R791212, R794847, R795100 and
R801832) as well as R239470. To identify an agonist for AT1
receptor, we initially syntesized R781253, which retains critical
side-chains of olmesartan (a carboxyl group and a hydroxyl group)
and has an additional 4-hydroxybenzyl (-CH2C6H4OH) group in
a biphenyltetrazole scaffold because phenol in Tyr
4 (Ang II) -
Asn
111 (AT1 receptor) interaction is a trigger for receptor
activation [19]. Next, we syntesized R781254, which contains a
methoxymethyl ether (-OCH2OMe) to understand the importance
of the hydroxyl group of phenol. R791212 has a 3-hydroxybenzyl
group instead of the 4-hydroxybenzyl group in R781253. In
addition, R794847 has a carbamoyl group instead of a carboxyl
group in the imidazole ring of R781253. Next, we syntesized
R795100, which contains an isopropyl group and a carbamoyl
group instead of a hydroxyisopropyl group and carboxyl group,
respectively. Finally, we syntesized R801832 which has a structure
similar to R794847, except for lacking the phenolic hydroxyl
group.
Pharmacological Properties of Olmesartan and Related
Compounds
First, we examined whether the various olmesartan-related
compounds retained the ability to bind to AT1- wild-type (WT)
and N111G mutant receptors (Table 1). Since we previously
reported that the AT1-N111G mutant receptor had high basal
activity in the absence of Ang II [23,24] and could be used to
determine the inverse agonism of olmesartan, we also analyzed the
binding affinities of olmesartan-related compounds in the mutant
receptor. The affinities of R791212, R794847 and R795100 in the
AT1-WT receptor were 10-fold less than that of olmesartan. In
addition, the affinities of R781254 and R801832 were reduced by
100-fold, which suggests that hydroxyphenyl moiety in the
biphenyltetrazole scaffold in olmesartan-related compounds pre-
vents binding to the AT1-WT receptor. On the other hand, all of
the olmesartan-related compounds showed higher binding affin-
ities, but ,2-fold compared with olmesartan, in AT1-N111G
receptor, suggesting that binding to the mutant receptor was
insensitive to the modification of olmesartan because the
conformation of the receptor is constitutively active.
Next, we analyzed whether the olmesartan-related compounds
induced agonism toward inositol phosphate (IP) production on the
AT1-WT and N111G receptors (Fig. 2). R781253 and R781254
retain inverse agonism. After modification of the phenolic group of
R781253, R791212 lost inverse agonism and showed neutral
antagonism. Interestingly, R794847 lost neutral antagonism, and
showed agonism, suggesting that modification of the carboxyl
group to the carbamoyl group in addition to insertion of a
hydroxyphenyl group in the biphenyltetrazole scaffold induced
agonism. Although R795100 and R801832 showed agonism, the
strength of these agonism were similar to that of R794847. All of
the olmesartan-related compounds showed similar degrees of
neutral antagonism and agonism toward the AT1-N111G receptor
compared with the pharmacological behaviors of these com-
pounds in the AT1-WT receptor. We selected R794847 as an
agonist. Thus, in subsequent analyses, olmesartan was used as an
inverse agonist, R239470 was a neutral antagonist, and R794847
was an agonist.
General Strategy Used to Identify AT1-WT Receptor
Contact Sites
To detect specific contact sites between olmesartan, R239470 or
R794847 and AT1-WT receptor in TM3, we mutated 13 amino
acid residues from Ser
105 to Phe
117 (S105A, A106G, S107A,
V108A, S109A, F110A, L112A, Y113F, Y113A, A114G, S115A,
V116A and F117A) and examined the binding affinities of these
compounds toward AT1-WT and mutant receptors (Table 2). The
expression levels of the AT1-WT and mutant receptors (point
mutations between Ser
105 and Phe
117) were within the same order
of magnitude (Table S1). The affinities of Ang II were almost the
same in all mutants, within ,2-fold, compared to AT1-WT
receptor. The affinity of olmesartan was reduced by .10-fold in
L112A and Y113F mutants compared with the AT1-WT receptor,
suggesting that Leu
112 and Tyr
113 in the AT1 receptor are
involved in binding to olmesartan. R239470, which has a chemical
structure similar to that of olmesartan but has a carbamoyl group
instead of a carboxyl group, exhibited a .10-fold reduction in
binding affinity to the L112A (54-fold reduction), Y113F (21-fold
reduction) and Y113A (183-fold reduction) mutants compared
with the AT1-WT receptor. R794847, which has a carbamoyl
Conformational Differences of AT1 Receptor
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group, also exhibited a 8.1-fold reduction in affinity in the Y113F
mutant, and a .10-fold reduction in affinity in the A106G (17-fold
reduction), V108A (51-fold reduction), Y113A (38-fold reduction)
and V116A (45-fold reduction) mutants. These results suggest that
Leu
112 and Tyr
113 are essential for binding between R239470 and
the AT1-WT receptor. Moreover, Ala
106, Val
108, Leu
112, Tyr
113
and Val
116 may be critical sites for the binding of R794847 to the
AT1-WT receptor. While both R239470 and R794847 have a
carbamoyl group, only R794847, which showed agonism, has a
hydroxyphenyl group, indicating that Ala
106 and Val
116 in the
AT1 receptor are probably important for binding to R794847 and
induce agonism.
Generation of Cysteine-substituted Mutant AT1 Receptor
To clarify the olmesartan-related compound-induced helical
movement of TM3 on the AT1 receptor, we introduced cysteine
substitutions into the region of TM3 that is known to be critical for
receptor activation [19] before performing a series of SCAM
experiments (Fig. S1).
As we reported previously [21], the percentage (%) inhibition of
125I-[Sar
1, Ile
8] AngII binding by methanethiosulphonate ethyl-
ammonium (MTSEA
+) reagent was approximately 30% on AT1
receptor, since Cys
76 in TM2 was accessible to water within the
ligand pocket. In addition, mechanical stretching increased the
accessibility of Cys
289 by inducing a change in the conformation of
TM7 [22]. To differentiate between single and multiple move-
ments of one or more native cysteines, we created TM3 residues
Figure 1. Construction of olmesartan-related compounds.
doi:10.1371/journal.pone.0037974.g001
Table 1. Binding affinities (Kd) of Ang II and R compounds to
AT1 wild-type (WT) and mutant receptors.
Ang II & ARBs WT N111G
nM
Ang II 1.260.5 0.660.2
Olmesartan 2.360.8 (1.0) 40619 (1.0)
R239470 0.860.3 (0.3) 15621 (0.4)
R781253 21610 (9.1) 52638 (1.3)
R781254 396680 (172) 73621 (1.8)
R791212 125626 (54) 3368 (0.8)
R794847 48612 (21) 35613 (0.9)
R795100 179684 (78) 52615 (1.3)
R801832 276622 (120) 1566 (0.4)
doi:10.1371/journal.pone.0037974.t001
Conformational Differences of AT1 Receptor
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105 to
Phe
117 using the C76A/C289A mutant genetic background and
evaluated each triple mutant for MTSEA sensitivity.
We examined whether the various cysteine-substituted mutants
retained the ability to bind AT1 receptor using radioligand binding
studies (Table 3). The expression levels of the AT1-WT and
mutant receptors substituted with cysteine were within the same
order of magnitude (Table S1). Binding studies with membranes
prepared from receptor-expressing cells showed that all AT1
mutant receptors were able to bind Ang II with high affinity.
Olmesartan, R239470 and R794847 showed higher binding
affinities toward all of the AT1 mutant receptors except for
C76A/Y113C/C289A mutant, which was not used in further
analysis.
Determination of Changes in the Conformation of TM3 in
the AT1 Receptor
We found that olmesartan, R239470 and R794847 acted as an
inverse agonist, a neutral antagonist and an agonist, respectively.
Therefore, we investigated the agonist-, neutral antagonist- and
inverse agonist-specific changes in receptor conformation with
regard to stabilization around TM3. Differences in cysteine
accessibility by ligand (-), olmesartan, R239470 and R794847 in
AT1-WT and mutant receptors are shown in Fig. 3. The %
inhibition of
125I-[Sar
1, Ile
8] AngII binding with the unliganded/
unoccupied receptor [ligands (-)] in the A106C, V108C, S109C,
N111C, L112C, S115C, V116C and F117C mutants in the
C76A/C289A background were significantly higher than those in
the C76A/C289A mutant with ligand (-), indicating that Ala
106,
Val
108, Ser
109, Asn
111, Leu
112, Ser
115, Val
116 and Phe
117 face
toward the ligand pocket of Ang II. In particular, the % inhibitions
of the C76A/V108C/C289A and C76A/L112C/C289A mutants
with ligand (-) were very high. Val
108 and Leu
112 definitely entered
the ligand pocket.
There were no significant differences in the % inhibition of
125I-
[Sar
1, Ile
8] Ang II binding in the A106C, V108C, N111C and
S115C mutants in the C76A/C289A background among
olmesartan, R239470 and R794847. Different values of %
inhibition were seen between the ligands in the S109C, L112C,
V116C and F117C mutants in the C76A/C289A background. For
example, Leu
112 shifts to further out of the ligand pocket with
olmesartan and R239470 than with ligand (-), since the %
inhibition in the C76A/L112C/C289A mutant with olmesartan
Figure 2. % inositol phosphate (IP) production with or without 1 mM of olmesartan and olmesartan-related compounds in COS1
cells transiently expressing the wild-type (WT) and N111G AT1 receptor. The test compounds were added 1 h before the measurement of
IP. 100% IP production indicates basal IP production in WT (1,0336149 cpm) and N111G (2,0876414 cpm) AT1 receptor-transfected cells. Ang II
(0.1 mM)-induced maximum IP production in WT and N111G AT1 receptor-transfected cells were 4,0376479 cpm and 4,1386362 cpm, respectively.
n=4–7, *p,0.05 vs. no treatment.
doi:10.1371/journal.pone.0037974.g002
Table 2. Binding affinities (Kd) of Ang II, olmesartan, R239470
and R794847 to AT1 wild-type (WT) and mutant receptors.
Receptor Kd
Ang II Olmesartan R239470 R794847
nM
WT 1.260.5 (1.0) 2.360.8 (1.0) 0.860.3 (1.0) 48612 (1.0)
S105 0.660.2 (0.5) 6.763.8 (1.8) 3.262.0 (4.0) 37623 (0.8)
A106G 0.960.2 (0.8) 6.162.2 (2.6) 4.861.5 (6.0) 7926202 (17)
S107A 0.560.1 (0.4) 2.560.5 (1.1) 1.360.2 (1.6) 59627 (1.2)
V108A 0.660.2 (0.5) 4.862.0 (2.1) 1.660.8 (2.0) 244861314 (51)
S109A 0.960.6 (0.8) 2.560.8 (1.1) 0.960.2 (1.1) 34611 (0.7)
F110A 0.860.3 (0.7) 2.660.5 (1.1) 1.260.3 (1.5) 68619 (1.4)
L112A 0.960.3 (0.8) 2767( 1 2 ) 4 3 612 (54) 3165 (0.6)
Y113F 1.861.0 (2.6) 5267( 2 3 ) 1 7 63 (21) 388654 (8.1)
Y113A 0.760.2 (1.0) 1263 (5.2) 146615 (183) 18046205 (38)
A114G 0.860.1 (0.7) 4.061.4 (1.7) 1.160.1 (1.4) 183617 (3.8)
S115A 1.260.1 (1.0) 3.161.7 (1.3) 1.360.4 (1.6) 150641 (3.1)
V116A 1.160.4 (0.9) 8.861.2 (3.8) 2.660.7 (3.2) 21546802 (45)
F117A 0.860.1 (0.7) 2.561.4 (1.1) 1.560.04 (1.9) 54619 (1.1)
doi:10.1371/journal.pone.0037974.t002
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Moreover, Leu
112 shifts to further out of the ligand pocket with
R794847 than with olmesartan or R239470, since the %
inhibition in the C76A/L112C/C289A with R794847 was
significantly lower than those with olmesartan and R239470.
We summarized whether Ser
109, Leu
112, Val
116 and Phe
117
become more or less accessible in the ligand pocket with
olmesartan, R794847 or R239470 compared to ligand (-)
(Fig. 4a). Since olmesartan showed less accessibility at Ser
109 and
Leu
112, TM3 was shifted outward from the ligand pocket (Fig.
4bc). In addition, since olmesartan induced greater accessibility at
Phe
117, TM3 might show slight counterclockwise rotation.
R239470 only induced a small conformational change in TM3.
Since only Leu
112 was less accessible with R239470, TM3 may be
only slightly shifted outward from the ligand pocket. R794847
showed conformational changes similar to those with olmesartan.
Since R794847 showed less accessibility at Ser
109 and Leu
112 and
more accessibility at Val
116 and Phe
117, TM3 was shifted outward
from the ligand pocket and showed greater counterclockwise
rotation than with olmesartan.
Molecular Modeling of the Interaction between ARBs and
the AT1 Receptor
A molecular model was constructed based on a consideration of
the interactions between the AT1 receptor and olmesartan,
R239470 or R794847 as suggested from the mutation experiments
and the changes in the conformation of TM3 in the AT1 receptor
induced by olmesartan, R239470 and R794847 using the SCAM
study (Fig. 5). The rotation and tilt of the TM helices are
introduced as described in the Methods. The distances between
Tyr
113 in the AT1 receptor and the hydroxyl group of olmesartan
and between Lys
199 and the carboxyl group are 3.4 and 2.6 A ˚,
respectively, which are reasonable distances for contributing to
electrostatic and/or hydrogen bond interactions. R239470 showed
slight changes in these distances (2.9 and 2.8 A ˚, respectively). In
addition, the distances with R794847 were similar to those with
R239470 (3.0 and 2.9 A ˚, respectively). Although R794847 did not
Table 3. Binding affinities (Kd) of Ang II, olmesartan, R239470
and R794847 to AT1 wild-type (WT) and mutant receptors.
Receptor Kd
Ang II Olmesartan R239470 R794847
nM
WT 1.260.5 (1.0) 2.360.8 (1.0) 0.860.3 (1.0) 48612 (1.0)
C76A/C289A 1.360.3 (1.1) 5.761.6 (2.5) 2.460.5 (3.0) 73620 (1.5)
C76A/A106C/
C289A
1.260.3 (1.0) 8.964.0 (3.9) 4.161.0 (5.1) 193673 (4.0)
C76A/S107C/
C289A
1.260.3 (1.0) 6.263.2 (2.7) 1.860.4 (2.3) 102619 (2.1)
C76A/V108C/
C289A
1.560.6 (1.3) 3261 (14) 1062( 1 3 ) 3 9 1 654 (8)
C76A/S109C/
C289A
1.360.3 (1.1) 2965 (13) 1163( 1 4 ) 9 6 618 (2.0)
C76A/F110C/
C289A
0.660.1 (0.5) 6.662.4 (2.9) 2.461.1 (3.0) 126613 (2.6)
C76A/N111C/
C289A
1.460.2 (1.2) 1264 (5.2) 5.463.0 (6.8) 180694 (3.8)
C76A/L112C/
C289A
1.660.3 (1.3) 6.162.1 (2.7) 3.261.3 (4.0) 6269 (1.3)
C76A/Y113C/
C289A
7.862.8 (6.5) 5706197 (248) 2726129 (340) 641962575
(134)
C76A/A114C/
C289A
1.360.2 (1.0) 5.562.6 (2.4) 1.660.7 (2.0) 128615 (2.7)
C76A/S115C/
C289A
1.760.4 (1.4) 6.561.8 (2.8) 4.261.6 (5.3) 6576114 (14)
C76A/V116C/
C289A
0.860.4 (0.7) 6.261.7 (2.7) 2.561.0 (3.1) 3963 (0.8)
C76A/F117C/
C289A
0.660.4 (0.5) 2.461.3 (1.0) 2.260.2 (2.8) 2969 (0.6)
doi:10.1371/journal.pone.0037974.t003
Figure 3. Changes in cysteine accessibility in COS1 cells expressing C76A/C289A mutant receptors in which the transmenbrane 3
residues from Ala
106 to Phe
117, except for position 113, were successively replaced by cysteine. 1 mM of ARBs, n=4–9, *p,0.05 vs. no
treatment. #p,0.05 vs. C76A/C289A.
doi:10.1371/journal.pone.0037974.g003
Conformational Differences of AT1 Receptor
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(3165 nM) compared with WT (48612 nM), Leu
112 was closer to
the centroid of the phenol ring of R794847 (3.6 A ˚) according to
molecular modeling. In addition, the other compounds do not
have a phenol ring in this position.
Discussion
In the present study, small molecules with similar structures,
olmesartan, R239470 and R794847, acted as an inverse agonist,
neutral antagonist and agonist, respectively. These molecules
induced specific actions in TM3 of AT1 receptor. Notably,
activation of most GPCRs induces a certain change in the
conformation of TM3. Our site-directed mutagenesis and SCAM
studies support the novel concept that ligand-induced changes in
the conformation of TM3 play a role in GPCR activation in a
native membrane environment (in situ).
Although it is now generally accepted that individual ligands
can induce different receptor conformations [25], little is known
about the actual differences at the molecular level. To gain
information about the transition from an inactive receptor
conformation to an active conformation, several different
techniques have been developed and used over the past decade.
While the crystal structures of GPCRs [4–10] obtained from the
rhodopsin, opsin, and ß1 and ß2-AR systems have recently been
described, the crystal structures of AT1 receptor have not been
elucidated. In addition, despite the importance of these structures
for GPCR research, crystallography has major limitations with
regard to characterizing and understanding the physiological
importance of receptors. Using a native membrane environment
(in situ), we systematically mutated the AT1 receptor and
examined the specific effects of olmesartan, R239470 and
R794847 on the conformation of the AT1 receptor with respect
to stabilization of TM3 as assessed by SCAM and molecular
modeling of the AT1 receptor.
While activating ligands (agonists) stabilize receptor conforma-
tions that increase signaling through G proteins, inhibiting ligands
(inverse agonists) stabilize other conformations that decrease the
basal, agonist-independent level of signaling. Although olmesartan
had inverse agonism, R239470, which has a non-acidic carbamoyl
group instead of a carboxyl group of olmesartan, lost inverse
Figure 4. A. Summary of cysteine accessibilityat Ser
109, Leu
112, Val
116 and Phe
117 with olmesartan, R239470 and R794847
compared to ligand (-). Less and More indicate that the AT1 receptor is less or more accessible to the ligand pocket, respectively. B. Helical wheel
representation of transmenbrane (TM)3 cysteine residues for ligand (-), olmesartan, R239470 and R794847. Olmesartan induced the outward
displacement and counterclockwise rotation of TM3. Dotted circle indicates the original position of TM3 without ligand. Accessible area indicates a
site of ligand pocket. C. Schematic view of TM3 movement derived from the SCAM results. TM3 without ligand is shown as a gray ribbon and TM3
with various ligands is represented as green ribbons. The ligands are colored magenta. (a) without ligand, (b) olmesartan, (c) R239470, (d) R794847.
doi:10.1371/journal.pone.0037974.g004
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moiety represents the difference between the chemical structures
of R239470 and R794847, and R794847 but not R239470
showed agonism. Thus, it may be possible to predict where to
modify a ligand to get inverse agonism or antagonism and where
to modify a ligand to get agonism.
Interestingly, R794847 and olmesartan produced the same
direction of rotation in TM3. The difference between R794847
and olmesartan was that there is more counterclockwise rotation
with R794847 than with olmesartan. Most of the olmesartan
contact sites in TM3 on the AT1 receptor that were identified in
the inverse agonism state of the receptor were also observed
following activation of the receptor by the agonist R794847. With
regard to ß2-AR, many of the interactions between the agonist BI-
167107 and the ß2-AR were similar to those observed with the
inverse agonist carazolol [9]. The hydroxyphenyl moiety, which
represents the difference between the chemical structures of
olmesartan and R794847, interacts with Leu
112 of the AT1
receptor. An agonist only has to disrupt one key intramolecular
interaction that is needed to stabilize the inactive state, since
constitutive receptor activity can result from single mutations of
amino acids from different regions of GPCRs [26]. Asn
111 of the
AT1 receptor is responsible for initiating receptor activation by
Ang II [19]. When R794847 interacts with Leu
112, R794847 may
change the position of Asn
111. Disruption of these stabilizing
interactions by R794847 changes the energy barrier for inducing
Figure 5. Putative binding mode of various ligands in AT1 receptor. Transmenbrane (TM)1–7 are shown as colored ribbons: blue (TM1), cyan
(TM2), green (TM3), lime green (TM4), yellow (TM5), orange (TM6) and red (TM7). Sidechains of the focused residues are shown as gray lines, and
ligands are represented as magenta sticks. The hydrogen bonds and electrostatic interactions are indicated by yellow dotted lines. The distance
between Leu
112 and the hydroxyphenyl moiety of R794847 is represented as a green dotted line. The unit of distance was A ˚. (a) without ligand, (b)
olmesartan, (c) R239470, (d) R794847.
doi:10.1371/journal.pone.0037974.g005
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in affinity in the V116A mutant. Since R794847 induced more
counterclockwise rotation than olmesartan, Val
116 was closer to
hydroxyphenyl group of R794847 (Fig. S2). The hydroxyphenyl
group and side-chain of Val
116 may form a weak hydrophobic
environment, and it may also need to stabilize the AT1 receptor.
Thus, R794847 stabilized receptor conformations in the active
state. While olmesartan and R794847 only showed slight
differences in binding sites, the specific stabilization of TM3
induced by each ligand was sufficiently different to signify
important differences in agonism.
When the agonist- and inverse agonist-bound structures in ß2-
AR are compared [9], the largest change is observed in TM6, with
11.4A ˚ movement of the helix at Glu
268. We only analyzed TM3
and did not examine other TMs, including TM6. In addition, the
largest differences in the ß2-AR relative to the inactive structure
were found at the cytoplasmic face of the receptor, with outward
displacement of TM5 and TM6 and inward movement of TM7
and TM3 [9]. In this study, we performed molecular modeling of
the interaction between R794847 and the AT1 receptor based on
SCAM results. Although we did not focus on the cytoplasmic face,
TM3 with R794847 was rotated counterclockwise. Although the
agonist- and inverse agonist-binding sites in the receptor are
similar, each ligand may induce differential changes in cytoplasmic
face of the receptor. In addition, Martin et al. [20] reported that
constitutive activation of AT1 N111G receptor causes slight
counterclockwise rotation of TM3. Agonist-activated AT1 receptor
and the constitutively active mutant of the AT1 receptor showed
the same counterclockwise rotation of TM3. However, since
agonist and inverse agonist induced the same direction of rotation
in TM3 in this study, the direction of rotation may not be
important for the receptor activation. Although the mechanism by
which agonists induce or stabilize these conformational changes
likely differs for different ligands and for different GPCRs, a better
understanding of the conformational changes in TM3 of AT1
receptor might provide new avenues for drug design. In addition,
since GPCR-targeted therapies include agonists as well as
antagonists, these structures should have a broader impact in
biological chemistry and pharmacology.
The movements of TMs 3 and 6 at the cytoplasmic side of the
membrane play an important role in the activation of G-protein-
coupled receptors [27,28]. For exsample, the salt bridge between
the highly conserved Arg
139 in TM3 and Glu
285 in TM6 (the ionic
lock) provides receptor stabilization [28]. R794847 might break
the ionic lock and induce agonism in the AT1 receptor.
In summary, to the best of our knowledge, this is the first
systematic and comprehensive analysis of receptor sites for three
small molecules with similar structures. Furthermore, all of the
experimental data were obtained with functional receptors present
in a native membrane environment (in situ). Since GPCRs share a
high degree of structural homology, our findings should be of
broad general relevance.
Materials and Methods
Materials
The following antibodies and reagents were purchased or
provided: the highly reactive, sulfhydryl-specific alkylating reagent
CH3SO2-SCH2CH2NH3
+ (methanethiosulfonyl ethyl-ammonium
[MTSEA
+], adduct size about 4.726 A ˚) (Toronto Research
Chemicals Inc., Ontario, Canada); olmesartan-related compounds
(Daiichi Sankyo Co., Tokyo, Japan); Ang II (Sigma-Aldrich, MO,
USA); and
125I-[Sar
1, Ile
8] Ang II (Amersham Biosciences,
Buckinghamshire, UK). The molecular structures of the ARBs
which we synthesized are shown in Fig. 1.
Mutagenesis and Expression of the AT1 Receptor and
Membrane Preparation
The synthetic rat wild-type (WT) AT1 receptor gene, cloned in
the shuttle expression vector pMT-3, was used for expression and
mutagenesis studies (Table 1), as described previously [19].
Cell Cultures, Transfections, Membrane Preparation
COS1 cells (African green monkey kidney fibroblast-like cell
line, #CRL-1650, American Type Culture Collection, VA, USA)
were cultured. The cells were maintained in 10% fetal bovine
serum (FBS) and penicillin- and streptomycin-supplemented
Dulbecco’s modified Eagle’s essential medium (Invitrogen) in 5%
CO2 at 37uC. In the experiments, cells without cell-growth
supplement were used. Cell viability in control experiments was
.95% by trypan blue exclusion analysis. The WT and mutant
AT1 receptors were transiently transfected into COS1 cells using
Lipofectamine 2000 liposomal reagent (Roche Applied Science)
according to the manufacturer’s instructions. Cell membranes
were prepared by the nitrogen Parr bomb disruption method using
0.25 M sucrose solution in the presence of protease inhibitors.
Competition Binding Study
The Kd and Bmax values of receptor binding were determined
by
125I-[Sar
1, Ile
8] AngII-binding experiments under equilibrium
conditions, as described previously [19]. Membranes expressing
the WT or mutant AT1 receptors were incubated with 100 pM
125I-[Sar
1, Ile
8] AngII for 1 h at 22uC in a volume of 125 ml. The
binding reaction was terminated by filtering the incubation
mixture through Whatman GF/C glass filters, and the residues
were extensively washed further with binding buffer. The bound
ligand fraction was determined from the counts per minute (cpm)
remaining on the membrane. Binding kinetics values were
determined as previously described [19].
Substituted Cysteine Accessibility Mapping (SCAM) Study
The SCAM method has been used to probe relative changes in
the conformation of constitutively active AT1 receptor [20–22]
and other GPCRs [29,30] by validating the presence of Cys
residues within the ligand pocket. We used a highly reactive,
sulfhydryl-specific reaction with methanethiosulfonyl ethyl-ammo-
nium (MTSEA
+), which reacts a billion times faster with water-
exposed and ionized Cys than with lipid-exposed and un-ionized
Cys. In this reaction, a positively charged sulfonylmethylammo-
nium group is added to a water-exposed Cys. Aliquots of cell
membranes are incubated with or without ARBs for 20 min in
phosphate buffer at room temperature. The membranes are then
diluted with same buffer and centrifuged. After washout the cell
membranes, the membranes are incubated with 2.5 mM
MTSEA
+ at room temperature for 2 min in HEPES buffer
(pH7.4). The Membranes are then diluted with same buffer to stop
the reaction and centrifuged. One hundred ml aliquots were used
to assay for
125I-[Sar
1,Ile
8]Ang II binding. The fractional
inhibition is calculates 1 2 [(specific binding after MTX reagent)
/ (specific binding without reagent)].
IP Production Study
Cells expressing the WT and mutant AT1 receptors were
incubated for 30 minutes at 22uC with or without the indicated
concentrations of ARBs. The cells were washed-out once with the
use of excess cold HBSS, and used in an IP production study.
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method, as described previously [16].
Molecular Modeling of AT1 Receptor-ARBs
For molecular modeling of the AT1 receptor with olmesartan,
the initial structure was prepared as previously reported [11]
followed by energy minimization. In addition, for a model of the
AT1 receptor without a ligand, the ligand was removed from the
final binding model of olmesartan as shown above, and then TM3
was manually tilted by 15 degrees, followed by energy minimiza-
tion. In all the other binding models, the final model with
olmesartan was used as an initial structure. For R239470,
extracellular-half (Gly
97-Tyr
113) and intracellular-half (Ala
114-
Val
131) of TM3 are tilted by 5 and 15 degrees, respectively, and
rotated by 5 degrees in a clockwise direction. The ligand was then
replaced by R239470, followed by energy minimization. For
R794847, TM2 and TM3 were rotated by 10 degrees in a
counterclockwise direction and TM6 and TM7 were moved away
from the pocket manually by 1.4 A ˚ for R794847. The ligand was
then replaced by R794847, followed by energy minimization.
Finally, the minimization was performed by MacroModel 9.7 or
9.8 (Schro ¨dinger Inc). The force field was set to OPLS2005 with a
GB/SA water solvation model and all of the atoms of the protein
backbone were fixed during energy minimization. The final
binding model was obtained by the Polak-Ribier Conjugate
Gradient (PRCG) method with a convergence threshold of 0.005
for less than 5000 iterations.
Statistical Analysis
The results are expressed as the mean 6 standard deviation of
three or more independent determinations. Significant differences
in measured values were evaluated with an analysis of variance
using Fisher’s t-test and a paired or unpaired Student’s t-test, as
appropriate. Statistical significance was set at ,0.05.
Supporting Information
Figure S1 Revised secondary-structure model of rat
wild-type AT1 receptor based on the structure of bovine
rhodopsin. Extracellular Cys
18-Cys
274 and Cys
101-Cys
180 form
disulfide bonds. The epitope tag attached to the C-terminal end
that was used for detection by the ID4 monoclonal antibody is
underlined. Bold residues indicate mutated sites.
(PPT)
Figure S2 Putative binding mode of R794847 and Val
116
of AT1 receptor. Transmenbrans (TMs) are shown as colored
ribbons: green (TM3), lime green (TM4), yellow (TM5) and
orange (TM6). Yellow dots indicate a hydrophobic environment.
(PPT)
Table S1 Maximal binding capacities (Bmax) of Ang II to
AT1 wild-type (WT) and mutants receptors.
(DOC)
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